Nomination Committee proposes Anders Ekblom as new Chairman of the Board in Xspray Pharma

Regulatory press release 2021-02-17

Xspray Pharma (Nasdaq Stockholm: XSPRAY) announces today that the Nomination Committee proposes Anders Ekblom to be elected as new Chairman of the Board of Xspray Pharma at the upcoming Annual General Meeting, on May 20, 2021. Anders Ekblom has extensive experience from the pharmaceutical industry globally, including as Executive Vice President Global Medicines Development at AstraZeneca and CEO and President of AstraZeneca AB Sweden. Anders Ekblom’s other current positions include Chairman of Elypta AB, Vice Chairman of LEO Pharma A/S, Board member of Alligator Bioscience AB and of Mereo Bio Pharma Group Plc. The current Chairman of the Board, Michael Wolff Jensen, announced in September 2020 that he declined re-election after seven years as Chairman of Xspray Pharma.

The Nomination Committee further proposes re-election of the Board members Gunnar Gårdemyr, Maris Hartmanis, Torbjörn Koivisto, Christine Lind, and Carl-Johan Spak. Anders Ekblom and Anders Bladh is proposed to be elected as new members of the Board. Anders Bladh is the CEO and Board member of Ribbskottet AB, which is the second largest owner in Xspray Pharma. The Nomination Committee also proposes Anders Ekblom to be elected as new Chairman of the Board. Consequently, the Nomination Committee proposes the Board to be expanded to seven members from previous six.

The Nomination Committee's additional proposals will be presented in the Notice to the Annual General Meeting 2021 that will be published in the beginning of April 2021.

Xspray Pharma's Nomination Committee consists of Gillis Cullin (Chairman) representing the Baltic Sea Foundation, Johan Gyllenswärd representing Ribbskottet AB, Caroline Sjösten representing Swedbank Robur funds and Michael Wolff Jensen, Chairman of the Board of Xspray Pharma.

About Xspray Pharma

Xspray Pharma AB (publ) is a pharma company with several product candidates in clinical development. Xspray Pharma uses its innovative, patented RightSize™ technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered to 55 in December 2020. The company’s leading product candidates, HyNap-Dasa, HyNap-Nilo, and HyNap-Sora, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Tasigna® (nilotinib) and Nexavar® (sorafenib). HyNap-Dasa is being developed in two versions, a generic and an improved version of Sprycel. HyNap-Nilo is being developed as an improved version of Tasigna and has has received orphan drug status from the US FDA. HyNap-Sora is being developed as an improved version of Nexavar®.

The company has patented manufacturing technology, equipment, and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com